KRAS and neoplasm: Recently, a comparative Oncomine NGS analysis from both tissue and plasma in NSCLC patients revealed that 24.13% (7/29) of mutations—such as EGFR L858R, KRAS G13D/Q61H, and several TP53 variants—were detected exclusively in plasma cfDNA, not in the tumor tissue.